10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

# CTLA-4

Catalog # PVGS1597

## Product Information

| | |
|---|---|
| **Primary Accession** | Q6GTR6 |
| **Species** | Mouse |
| **Sequence** | Ala37-Phe162 |
| **Purity** | > 90% as analyzed by SDS-PAGE |
| **Endotoxin Level** | |
| **Biological Activity** | Immobilized Mouse B7-1/CD80 Protein, His Tag at 2.0 μg/ml can bind CTLA-4, mFc, Mouse with $EC_{50}$=12.57 ng/ml when detected by M6 Goat Anti Mouse FC. |
| **Expression System** | CHO |
| **Formulation** | Lyophilized from a 0.2 μm filtered solution in PBS. |
| **Reconstitution** | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in dd$H_2O$ or PBS up to 100 μg/ml. |
| **Storage & Stability** | Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |

## Additional Information

| | |
|---|---|
| **Target Background** | CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is also known as CD152, is an Inhibitory receptor acting as a major negative regulator of T-cell responses. CTLA-4 is a member of the immunoglobulin superfamily, which is expressed on the surface of T cells and transmits an inhibitory signal to T cells. CTLA-4 and CD28 are homologous receptors expressed by both CD4+ and CD8+ T cells, which mediate opposing functions in T-cell activation. Both receptors share a pair of ligands expressed on the surface of antigen-presenting cells (APCs). The affinity of CTLA-4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. |

## Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.